ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 144 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,418,769 | -13.4% | 148,874 | 0.0% | 0.06% | -9.7% |
Q1 2023 | $1,637,614 | -25.7% | 148,874 | 0.0% | 0.06% | -25.3% |
Q4 2022 | $2,203,335 | -22.6% | 148,874 | 0.0% | 0.08% | -28.4% |
Q3 2022 | $2,845,000 | -10.3% | 148,874 | 0.0% | 0.12% | -7.2% |
Q2 2022 | $3,173,000 | +25.2% | 148,874 | +13.1% | 0.12% | +40.4% |
Q1 2022 | $2,535,000 | -7.1% | 131,633 | 0.0% | 0.09% | +1.1% |
Q4 2021 | $2,730,000 | -13.2% | 131,633 | 0.0% | 0.09% | -12.9% |
Q3 2021 | $3,145,000 | -12.4% | 131,633 | 0.0% | 0.10% | -13.7% |
Q2 2021 | $3,592,000 | -5.7% | 131,633 | 0.0% | 0.12% | -10.7% |
Q1 2021 | $3,808,000 | – | 131,633 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |